For example, treatment with anti-CCL2 neutralizing antibodies significantly reduces the number of macrophages in human RCC xenografts transplanted into SCID mice, which reduces micro-vessel density, and growth of xenografted tumors (53). The gene discussed is CCL2; the disease is renal cell carcinoma.